| Title |
Intranasal Treatment of Central Nervous System Dysfunction in Humans
|
|---|---|
| Published in |
Pharmaceutical Research, November 2012
|
| DOI | 10.1007/s11095-012-0915-1 |
| Pubmed ID | |
| Authors |
Colin D. Chapman, William H. Frey, Suzanne Craft, Lusine Danielyan, Manfred Hallschmid, Helgi B. Schiöth, Christian Benedict |
| Abstract |
One of the most challenging problems facing modern medicine is how to deliver a given drug to a specific target at the exclusion of other regions. For example, a variety of compounds have beneficial effects within the central nervous system (CNS), but unwanted side effects in the periphery. For such compounds, traditional oral or intravenous drug delivery fails to provide benefit without cost. However, intranasal delivery is emerging as a noninvasive option for delivering drugs to the CNS with minimal peripheral exposure. Additionally, this method facilitates the delivery of large and/or charged therapeutics, which fail to effectively cross the blood-brain barrier (BBB). Thus, for a variety of growth factors, hormones, neuropeptides and therapeutics including insulin, oxytocin, orexin, and even stem cells, intranasal delivery is emerging as an efficient method of administration, and represents a promising therapeutic strategy for the treatment of diseases with CNS involvement, such as obesity, Alzheimer's disease, Parkinson's disease, Huntington's disease, depression, anxiety, autism spectrum disorders, seizures, drug addiction, eating disorders, and stroke. |
Mendeley readers
The data shown below were compiled from readership statistics for 419 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | <1% |
| Cuba | 2 | <1% |
| United States | 2 | <1% |
| United Kingdom | 1 | <1% |
| Russia | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 410 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 61 | 15% |
| Student > Ph. D. Student | 58 | 14% |
| Student > Master | 57 | 14% |
| Student > Bachelor | 35 | 8% |
| Student > Doctoral Student | 28 | 7% |
| Other | 78 | 19% |
| Unknown | 102 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 64 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 54 | 13% |
| Agricultural and Biological Sciences | 37 | 9% |
| Psychology | 36 | 9% |
| Neuroscience | 29 | 7% |
| Other | 74 | 18% |
| Unknown | 125 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#5,415,901
of 25,654,806 outputs
Outputs from Pharmaceutical Research
#546
of 3,005 outputs
Outputs of similar age
#39,571
of 198,988 outputs
Outputs of similar age from Pharmaceutical Research
#5
of 26 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,005 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,988 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.